You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Mobile-Delivered Personalized Feedback Intervention for Black Individuals who Engage in Hazardous Drinking
SBC: HEALTH BEHAVIOR SOLUTIONS INC Topic: 400PROJECT SUMMARY/ABSTRACT Black persons are the second largest racial minority group in the United States (US) and experience striking health disparities, particularly in terms of hazardous drinking and co-occurring elevated anxiety. The co- occurrence of these risk factors contributes to worse physical/mental health outcomes among Black individuals. Few interventions to date have targeted hazardou ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Ambulatory cryocooling therapy device
SBC: NANOHMICS INC Topic: NIAMSPI: Savoy Project Summary Tissue protection following injury begins with shutting down vasodilation and limiting subsequent swelling through the application of cold. In many cases, the cold comes in the form of bags of ice or frozen cold packs, or commercial cooling products such ice packs or ice pack holding limb wraps. In others it may be via a chilled water circulator device, for example the Po ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
SBC: BIOSTRATAGIES LC Topic: NICHDMucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
SBC: Nephropathology Associates, PLC Topic: 400Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Finding undiagnosed ATTR-CM patients using AI technology in clinical settings
SBC: ATOMO INC Topic: NHLBIProject Summary: Transthyretin Amyloidosis with cardiac myopathy, ATTR-CM, represent a serious healthcare issue. ATTR-CM is involved in 13% of heart failure, 16% of transcatheter aortic-valve replacement, and 5% of individuals with presumed hypertrophic cardiomyopathy. The primary challenge is that most patients are undiagnosed or their diagnosis is delayed for multiple years. Since the damage ATT ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Pharmacological Treatment for Preeclampsia
SBC: ARTEMIS BIOTECHNOLOGIES LLC Topic: NICHDNovel Pharmacological Treatment for Preeclampsia AbstractPreeclampsia (preE) is a serious hypertensive complication of pregnancy often accompanied by proteinuria and edema, sometimes with encephalopathy, seizures, and hepatic failure. PreE complicates 5 to 10% of pregnancies and is a major cause of maternal and fetal morbidity and mortality worldwide. Nevertheless, an effective therapy for this di ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection
SBC: BASE PAIR BIOTECHNOLOGIES INC Topic: NIBIBProject Summary/Abstract The United States is experiencing an epidemic of unprecedented scope with heroin use resurging and a troubling pervasive increase in abuse of prescription opioids such as fentanyl, fentanyl derivatives, methadone, oxycodone and hydrocodone. More than 6 out of 10 drug overdoses are now opioid-related, resulting in ~90 deaths/day and a more than $75B/year economic impact. Ad ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Medical Device Identifier to Improve Emergency Triage
SBC: BRIDGESOURCE MEDICAL, CORP. Topic: RProject Summary Abstract Cardiovascular Implantable Electronic Devices (CIEDs) like a Permanent Pacemaker or Implantable Defibrillator are implanted in over 3 million Americans, with the average age of implantation in the 60s, 40% ≥ 70 years old, and 28% ≥ 80 years old. When a patient presents to the Emergency Department (ED) with an unknown CIED, reprogramming of the device is often necessary ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Advancing Fluorescence Imaging-guided Partial Nephrectomy with ClearICG
SBC: CLEARNANO INC Topic: 102AbstractPartial nephrectomy is becoming an increasingly important treatment for kidney cancer because more than 60% of kidney cancer cases are diagnosed in early, localized stages. Compared to radical nephrectomy, partial nephrectomy offers much better preservation of renal function while having an equivalent oncological efficacy for the localized kidney cancer, thereby significantly reducing the ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
SBC: BIOSTRATAGIES LC Topic: 105PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health